The World Health Organization (WHO) has concluded a meeting on Ebola R&D to look at lessons learned from the outbreak and develop a roadmap for future epidemics. Dr. Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said the Geneva meeting aimed to “come up with a new framework for R&D for diseases with epidemic potential and other health threats, so that next time we can be better prepared, faster and more effective.” Kieny said, “If something like Ebola ever happens again, the world needs to be ready with a blueprint for an R&D preparedness plan with clear rules, platforms for information sharing, established processes to expedite development and clinical trials—to activate coordinated action and limit the damage.” The meeting in Geneva, Switzerland, took place as an independent panel of experts tasked to assess the UN global health agency’s response to the Ebola outbreak in West Africa concluded in a report that “at present, WHO does not have the operational capacity or culture to deliver a full emergency public health response” and urged investments by its member states to make it fit for purpose. “Ebola is not the only epidemic-prone disease for which there are no medicines, vaccines or diagnostics. Nor is this the first time the world has been caught unprepared in the face of an epidemic,” said Kieny. “With more frequent travel, globalized trade and greater interconnectedness between countries, disease outbreaks that once used to be localized and quickly extinguished now have a much greater chance of spreading more widely. Therefore, we as a global community need to be prepared for such a possibility in the future.” To date, the Ebola outbreak in West Africa has affected more than 26,000 people and left some 11,000 dead. Dr. Margaret Chan, WHO director-general, said the Ebola R&D effort has mobilized people, institutions and resources in ways never before seen in an “otherwise horrific human calamity” and noted that the world was “likely very close to having a vaccine that can protect against Ebola.” Kieny said that thanks to “this joining of forces from all corners of the world and different sectors accelerating all actions, we now have commercial diagnostics to detect Ebola, and at least two possibly effective vaccines. These results would normally have taken five to 10 years. All this was done in less than 10 months. Even as Ebola wanes and some of the R&D efforts may not reach the goals aspired, the pioneering work done so far can be leveraged to put in place standards and best practices to improve expedited data and results sharing.”
Saturday, March 19, 2016
WHO draws lessons from Ebola to prepare roadmap for future epidemics
Related Posts:
McMaster researchers test fecal transplantation to treat ulcerative colitis Two new studies led by researchers from the Farncombe Family Digestive Health Research Institute at McMaster University show that transplantation of fecal matter may be a useful tool in the fight against ulcerative coli… Read More
Massachusetts General Hospital launches phase II trial of BCG vaccine to reverse type 1 diabetes FDA approval of trial testing generic vaccine announced at ADA Scientific Sessions A phase II clinical trial testing the ability of the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes … Read More
More than 95% of the global population has at least one health problem, study finds The largest and most in-depth study of global health trends to date finds that more than 95% of the world’s population has health problems, with more than a third of us experiencing five or more conditions. The results… Read More
NightstaRx and The University of Alberta announce the start of the first Canadian gene therapy study to treat Choroideremia NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies to patients, announces that the University of Alberta, has begun enrolling and dosing subjects in a … Read More
FDA strengthens heart safety warnings on painkillers People should think carefully about taking these drugs, both over-the-counter versions and prescription pills, the FDA says. It’s asking manufacturers to change the labels.”They used to say they might cause risk of heart … Read More
About Blogger:

Hi,I,m Basim from Canada I,m physician and I,m interested in clinical research feild and web development.you are more welcome in our professional website.all contact forwarded to basimibrahim772@yahoo.com.
Let's Get Connected: Twitter | Facebook | Google Plus| linkedin
0 comments:
Post a Comment